Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.31 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.31 |
| ▸ | KDM1A | O60341 | 1/20 | 0.30 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.30 |
| ▸ | PGR | P06401 | 1/20 | 0.30 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.30 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.30 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.30 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.30 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.30 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10275295 | 0.86 | MAPK14 (0.37) | PARP1PARP2KDM1APGRNR3C2 | |
| SCHEMBL10275521 | 0.85 | AR (0.36) | KDM1AEGLN2PGRNR3C2GABRA1 | |
| SCHEMBL10276103 | 0.83 | PGR (0.37) | PGRNR3C2 | |
| SCHEMBL10275391 | 0.82 | PGR (0.38) | PGRNR3C2 | |
| SCHEMBL10276075 | 0.76 | PARP1 (0.36) | PARP1PARP2KDM1AGABRA1GABRG2 | |
| SCHEMBL10275823 | 0.76 | ARF6 (0.46) | PARP1PARP2KDM1AGABRA1GABRG2 | |
| SCHEMBL10275293 | 0.76 | KDM1A (0.39) | KDM1AEGLN2PGRNR3C2GABRA1 | |
| SCHEMBL10275641 | 0.76 | PLAT (0.40) | PARP1PARP2KDM1AGABRG2GABRB3 | |
| SCHEMBL10275156 | 0.75 | ARF6 (0.45) | PARP1PARP2KDM1A | |
| SCHEMBL10280465 | 0.75 | GCGR (0.40) | PARP1PARP2KDM1APGRNR3C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120178915-A1 | PYRIMIDINE DERIVATIVES AND ANALOGS, PREPARATION METHOD AND USE THEREOF | XU LIFENG (US) | 2012-07-12 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178915-A1 | PYRIMIDINE DERIVATIVES AND ANALOGS, PREPARATION METHOD AND USE THEREOF | TYMP, TYMS, ADORA3 | PARP1 2647/4885PARP2 3330/4885KDM1A 3996/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.